• Air Traffic Control
  • Govt Finance Report
  • Pension Reform
  • Events
  • Reason facebook
  • Reason twitter
  • Reason youtube
Reason Foundation
  • About
    • About Us
    • Contact Us
    • Email Newsletters
    • Events
    • FAQs
    • Jobs & Internships
    • Savas Award
    • Shop
    • Staff
    • Trustees & Officers
  • Experts

      Browse Our Experts

      • Aaron Smith
        Director of Education Reform
      • Adrian Moore
        Vice President, Policy
      • Baruch Feigenbaum
        Senior Managing Director, Transportation Policy
      • Geoff Lawrence
        Research Director
      • Guy Bentley
        Director of Consumer Freedom
      • Leonard Gilroy
        Vice President, Government Reform
      • Robert Poole
        Director of Transportation Policy
      • Vittorio Nastasi
        Director of Criminal Justice Policy
      • View All Experts
  • Topics

      Browse Our Topics

      • Air Traffic Control
      • Annual Highway Report
      • Consumer Freedom
      • Criminal Justice Reform
      • Drug Policy
      • Education
      • Gov’t Financial Transparency
      • Pension Reform
      • Technology
      • Transportation
      • Urban Growth and Land Use
      • View All Topics
  • Publications
    • Latest
    • Government Financial Project
    • Annual Highway Report
    • Annual Pension Report
    • Annual Privatization Report
    • Aviation Newsletter
    • Backgrounders
    • Commentaries
    • Data Visualization
    • Education Newsletter
    • Email Newsletters
    • Pension Reform Newsletter
    • Policy Studies
    • Psychedelics Newsletter
    • Public Schools Without Boundaries
    • Testimony
    • Transportation Newsletter
    • Amicus Briefs
  • Reason.com
  • Donate
    • Donate Online
    • Donate Crypto
    • Ways To Give
    • Torchbearer Society
    • Planned Giving

Policy Studies

  • By Topic
  • By Author
  • By Date
Clear Filters

  • Optimal framework for the state regulation of hemp cannabinoids 
    Optimal framework for the state regulation of hemp cannabinoids 

    The hemp cannabinoid market has grown into a $3 billion interstate industry.

    Backgrounder by Michelle Minton and Geoffrey Lawrence March 25, 2025

  • The implications of federal cannabis rescheduling
    The implications of federal cannabis rescheduling

    While the optimal solution would be to remove cannabis from the list of controlled substances entirely, moving it to Schedule III presents both immediate and long-term advantages over its current Schedule I designation.

    Policy Brief by Michelle Minton January 23, 2024

  • Getting cannabis legalization right in Hawaii
    Getting cannabis legalization right in Hawaii

    Hawaii may be poised to become the 25th state to legalize the recreational use of cannabis for adults aged 21 and over.

    Policy Brief by Michelle Minton and Geoffrey Lawrence March 29, 2024

  • A framework for federal and state hemp-derived cannabinoid regulation
    A framework for federal and state hemp-derived cannabinoid regulation

    The growing popularity of hemp-derived products has stimulated significant legislative attention in recent years, with over 90 regulatory proposals introduced in state legislatures in 2024 alone.

    Policy Brief by Michelle Minton and Geoffrey Lawrence September 19, 2024

  • How state reforms changed federal enforcement of marijuana prohibition
    How state reforms changed federal enforcement of marijuana prohibition

    While formal federal marijuana law has persisted unchanged amid state-level reforms, federal marijuana enforcement on the ground has changed dramatically.

    Policy Brief by Douglas Berman and Alex Fraga September 22, 2022

  • How drug decriminalization affects policing
    How drug decriminalization affects policing

    With the diminished capacity and incentive to pursue drug possession arrests, police can redirect resources toward crimes with victims, crime prevention, and public safety.

    Policy Brief by Marcus W. Brown September 22, 2022

  • FAQ: Timeline for FDA ibogaine approval
    FAQ: Timeline for FDA ibogaine approval

    It can take between 5 and 12 years to complete a drug trial, but the timeline to drug approval can vary significantly depending on the type of treatment.

    FAQ by Gregory Ferenstein November 4, 2025

  • A policy framework for personal psychedelics licenses
    A policy framework for personal psychedelics licenses

    Psychedelic licenses for consumers have advantages over the current approach in two U.S. states that rely on professionals to dispense and facilitate services.

    Policy Brief by Gregory Ferenstein February 22, 2024

  • K-12 open enrollment in Wisconsin: Key lessons for other states
    K-12 open enrollment in Wisconsin: Key lessons for other states

    Wisconsin's public school open enrollment program serves over 70,000 students and can be a model for other states.

    Policy Brief by Will Flanders February 9, 2023

  • Ibogaine offers major promise in treating addiction, mental health
    Ibogaine offers major promise in treating addiction, mental health

    Ibogaine has the potential to transform the lives of millions of Americans struggling with addiction and mental health challenges.

    Backgrounder by Madison Carlino and Leonard Gilroy April 24, 2025

  • Ibogaine could transform public spending on opioid treatment
    Ibogaine could transform public spending on opioid treatment

    Using ibogaine as a treatment for opioid use disorder could be significantly more cost-effective than traditional medication-assisted treatments.

    Backgrounder by Madison Carlino November 5, 2025

  • Modernizing psilocybin policy to improve mental health outcomes
    Modernizing psilocybin policy to improve mental health outcomes

    Psychedelics have the potential to be more effective than conventional drugs now being used to treat a range of mental health disorders.

    Policy Brief by Madison Carlino May 23, 2023

  • Ibogaine treatment for opioid use disorder
    Ibogaine treatment for opioid use disorder

    Policymakers should consider ibogaine as a potential alternative treatment for opioid use disorder.

    Policy Brief by Madison Carlino March 15, 2024

  • Psychedelic treatment for neurodegenerative disorders
    Psychedelic treatment for neurodegenerative disorders

    Recent research suggests that psychedelics, such as psilocybin and LSD, show strong potential as effective treatments for neurodegenerative disorders.

    Policy Brief by Madison Carlino January 9, 2025

  • Video Game Loot Boxes: Anatomy of a Moral Panic
    Video Game Loot Boxes: Anatomy of a Moral Panic

    There is no evidence to suggest that loot box spending is excessive among adults or adolescents or that it is responsible for any widespread harm.

    Policy Brief by Matthew McCaffrey July 19, 2023

  • The case for Connecticut’s fiscal guardrails
    The case for Connecticut’s fiscal guardrails

    The “fiscal guardrails” have saved Connecticut more than $170 million and could save $7 billion over the next 25 years.

    Policy Brief by Mariana Trujillo, Jordan Campbell, Steve Vu and Truong Bui September 26, 2024

  • Report: State and local governments have $6.1 trillion in debt
    Report: State and local governments have $6.1 trillion in debt

    State and local debt is over $100 billion in 16 states and exceeds $50 billion in 27 states. California’s state and local governments have over $1 trillion in debt.

    Financial Transparency Project by Mariana Trujillo and Jordan Campbell October 23, 2025

  • Report ranks every state’s debt, from California’s $497 billion to South Dakota’s $2 billion
    Report ranks every state’s debt, from California’s $497 billion to South Dakota’s $2 billion

    Study finds state governments have a total of $2.7 trillion in debt, with 26 states exceeding $20 billion in debt each and 10 states over $70 billion.

    Financial Transparency Project by Mariana Trujillo and Jordan Campbell October 23, 2025

  • First
  • Prev
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • Next

Follow

  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS

Email Updates

Get weekly updates from Reason.

This field is for validation purposes and should be left unchanged.

More About Reason Foundation

  • About
  • Contact
  • Donate
  • Email Newsletters
  • Events
  • Jobs and Internships
  • Policy Research
  • Reason magazine
  • Shop

Contact

Reason Foundation
5737 Mesmer Ave.
Los Angeles, CA 90230
(310) 391-2245

1630 Connecticut Ave NW
Suite 600
Washington, DC 20009
(202) 986-0916

Privacy Policy
Accessibility

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
Copyright © 2026 Reason Foundation